PRDX3: A Potential Drug Target for Neurological Disorders (G10935)

Target Name: PRDX3

NCBI ID: G10935

PRDX3

PRDX3: A Potential Drug Target for Neurological Disorders

PRDX3 (Protamine DOPA-Choline) is a protein that is expressed in various tissues throughout the body, including the brain, and is involved in the synthesis and degradation of the amino acid choline. Choline is a crucial molecule that is found in many foods, including eggs, meat, and plants, and is also available as a dietary supplement. It is a key component of the nervous system and is involved in the development and maintenance of healthy brain function.

Research has suggested that PRDX3 may have a variety of potential functions, including its role in the treatment of various neurological disorders. PRDX3 has been shown to interact with several other proteins, including the neurotransmitter dopamine, which is involved in the transmission of signals in the brain. This suggests that PRDX3 may be involved in the regulation of dopamine levels and could potentially be a drug target for the treatment of disorders related to dopamine transmission, such as Parkinson's disease.

Additionally, PRDX3 has been shown to interact with the protein brain-derived neurotrophic factor (BDNF), which is a protein that is involved in the maintenance of brain cells and is often decreased in the brains of individuals with neurodegenerative disorders. This suggests that PRDX3 may be involved in the treatment of neurodegenerative disorders.

PRDX3 is also shown to interact with the protein heat shock protein (HSP70), which is involved in the regulation of protein structure and function. This suggests that PRDX3 may be involved in the regulation of protein structure and function, which could potentially be a drug target for the treatment of a variety of disorders.

In addition to its potential role in the treatment of neurological disorders, PRDX3 has also been shown to have potential as a biomarker for a variety of neurological disorders. For example, PRDX3 has been shown to be decreased in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells. This suggests that PRDX3 may be a potential biomarker for Alzheimer's disease.

Furthermore, PRDX3 has also been shown to be decreased in the brains of individuals with Parkinson's disease, another neurodegenerative disorder that is characterized by the progressive loss of brain cells. This suggests that PRDX3 may be a potential biomarker for Parkinson's disease.

In conclusion, PRDX3 is a protein that has been shown to interact with several other proteins that are involved in the development and maintenance of healthy brain function. Its potential roles in the treatment of various neurological disorders, including Alzheimer's disease and Parkinson's disease, make PRDX3 a promising target for future research and development. Further studies are needed to fully understand the role of PRDX3 in the treatment of neurological disorders and to determine its potential as a biomarker for these disorders.

Protein Name: Peroxiredoxin 3

Functions: Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides (PubMed:7733872, PubMed:17707404, PubMed:29438714, PubMed:33889951). Acts synergistically with MAP3K13 to regulate the activation of NF-kappa-B in the cytosol (PubMed:12492477). Required for the maintenance of physical strength (By similarity)

The "PRDX3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDX3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets